|
|
|
| Efficacy of high-dose ambroxol combined with imipenem in treatment of elderly patients with severe pneumonia treated by mechanical ventilation |
| YAN Bin1, ZHAO Guifeng1, ZHANG Mei2 |
| 1. Department of Intensive Care Unit, 2. Department of Gynecology and Obstetrics, Characteristics Medical Center of PLA Rocket Force, Beijing 100088, China |
|
|
|
|
Abstract Objective To investigate the efficacy and safety of high-dose ambroxol combined with imipenem in the treatment of elderly patients with severe pneumonia treated by mechanical ventilation. Methods A total of 86 elderly (≥80 years old) patients with severe pneumonia admitted to ICU of Characteristics Medical Center of PLA Rocket Force from June 2019 to June 2023 were divided into two groups by random number table method, they were divided into two groups. The control group included 40 patients who received conventional-dose ambroxol combined with imipenem treatment, while the study group included 46 patients who received high-dose ambroxol [15 mg/(kg·d)] combined with imipenem treatment. The efficacy of the two groups was compared after treatment, including lung imaging, duration of mechanical ventilation, length of ICU stay. APACHE Ⅱ, SOFA, CPIS, changes in inflammatory factors and adverse reactions. Results Compared with the control group, the duration of mechanical ventilation of the study group was shorter[(8.15±1.31)d vs. (7.13±1.53)d, P<0.05],disappearance time of shadow on chest radiograph was faster[(7.80±1.02)d vs. (6.61±0.97)d, P<0.05]. The duration of ICU stay was shorter [(16.25±1.78)d vs. (14.37±2.15)d, P<0.05], and the lesion absorption rate was higher[(65.95±7.73)% vs. (78.96±9.11)%, P<0.05]. After treatment, APACHE Ⅱ [(7.17±1.07) vs. (8.25±1.12), P<0.05], SOFA [(3.15±0.51) vs. (4.21±0.96), P<0.05], CPIS[(3.18±0.89) vs. (3.80±0.75), P<0.05], PCT[(0.16±0.07) μg/L vs. (0.25±0.12)μg/L, P<0.05], CRP[(5.15±3.11)mg/L vs. (8.51±2.96)mg/L, P<0.05], IL-6 [(15.28±9.89) ng/L vs. (25.20±1.75) ng/L, P<0.05]of the study group decreased faster. There was no significant difference in the incidence of adverse reactions between the two groups during the observation period (P>0.05). Conclusions High-dose ambroxol combined with imipenem in the treatment of elderly patients with severe pneumonia treated by mechanical ventilation can shorten the duration of mechanical ventilation and ICU stay, and the safety is good.
|
|
Received: 16 October 2023
|
|
|
|
|
|
| [6] |
卢 娇,方 敏.重症肺部感染与免疫紊乱:问题与展望[J].中国实用内科杂志, 2022, 42(3): 196-201.
|
| [1] |
王 萌,吴素丽,王宏鑫,等.盐酸氨溴索治疗呼吸机相关肺部感染的效果[J].中华医院感染学杂志,2019,29(14):2104-2107.
|
| [7] |
程 龙,李建生,马利军,等.老年细菌性肺炎患者免疫功能的变化[J].中华老年医学杂志, 2001 (6):32-35.
|
| [2] |
刘金连.不同剂量氨溴索联合机械通气治疗老年重症肺炎的疗效观察[J].中国现代药物应用, 2022, 16(12):133-135.
|
| [8] |
陈业民,黄文杰,李胜利,等.重症肺炎大鼠干扰素-γ、白细胞介素-6和肿瘤坏死因子-α含量变化[J].中国病理生理杂志,2007(3):492-494.
|
| [3] |
胡建华,敖 琳,张小萍.呼吸衰竭行机械通气患者并发呼吸机相关性肺炎的相关危险因素及其预防措施分析[J].当代护士,2021,28(12):20-23.
|
| [9] |
周 敏.呼吸支持治疗的现状与发展[J].齐鲁护理杂志,2019,25(7):13-16.
|
| [10] |
Hu M, Zhu Z, Wu Y, et al. Exploring the potential of hydrophilic matrix combined with insoluble film coating: preparation and evaluation of ambroxol hydrochloride extended release tablets[J]. AAPS Pharm Sci Tech, 2020, 21(3):93.
|
| [4] |
Torres A, Chalmers J D, Dela Cruz C S, et al. Challenges in severe community-acquired pneumonia: a point-of-view review[J]. Intensive Care Med, 2019, 45(2):159-171.
|
| [11] |
李俊辉,韩志强.设置最佳呼气末正压的临床应用进展[J].临床麻醉学杂志, 2023, 39(1): 98- 102.
|
| [5] |
Girón R M, Ibáñez A, Gómez-Punter R M, et al. New evidence in severe pneumonia: imipenem/cilastatin/relebactam[J]. Rev Esp Quimioter,2022,35 (Suppl 1):46-49.
|
| [12] |
Cataldi M, Sblendorio V, Leo A, et al. Biofilm-dependent airway infections: a role for ambroxol?[J]. Pulm Pharmacol Ther, 2014,28(2):98-108.
|
| [6] |
卢 娇,方 敏.重症肺部感染与免疫紊乱:问题与展望[J].中国实用内科杂志, 2022, 42(3): 196-201.
|
| [13] |
Wang Y, Li X, Wang D, et al. In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant acinetobacter baumannii[J]. Lett Appl Microbiol,2020,70 (3):189-195.
|
| [7] |
程 龙,李建生,马利军,等.老年细菌性肺炎患者免疫功能的变化[J].中华老年医学杂志, 2001 (6):32-35.
|
| [14] |
李 慧,徐效峰,丘绍校.大剂量氨溴索对急性肺损伤/急性呼吸窘迫综合征疗效的系统评价[J].中国呼吸与危重监护杂志, 2012,11(5):459-464.
|
| [8] |
陈业民,黄文杰,李胜利,等.重症肺炎大鼠干扰素-γ、白细胞介素-6和肿瘤坏死因子-α含量变化[J].中国病理生理杂志,2007(3):492-494.
|
| [9] |
周 敏.呼吸支持治疗的现状与发展[J].齐鲁护理杂志,2019,25(7):13-16.
|
| [15] |
孔 颖.大剂量氨溴索联合左氧氟沙星治疗老年慢性阻塞性肺疾病伴重症肺炎患者的临床效果[J].医疗装备,2021,34(10):77-78.
|
| [10] |
Hu M, Zhu Z, Wu Y, et al. Exploring the potential of hydrophilic matrix combined with insoluble film coating: preparation and evaluation of ambroxol hydrochloride extended release tablets[J]. AAPS Pharm Sci Tech, 2020, 21(3):93.
|
| [16] |
王 芳,周秋云,鲁 涛.亚胺培南西司他丁钠或美罗培南治疗早期肺癌合并重症肺部感染[J].中国临床研究,2022,35(9):1305-1309.
|
| [11] |
李俊辉,韩志强.设置最佳呼气末正压的临床应用进展[J].临床麻醉学杂志, 2023, 39(1): 98- 102.
|
| [17] |
李慧敏,李多磊,许晓雨,等.清开灵注射液联合亚胺培南西司他丁钠治疗老年重症肺炎的临床研究[J].现代药物与临床,2020,35(9):1777-1781.
|
| [12] |
Cataldi M, Sblendorio V, Leo A, et al. Biofilm-dependent airway infections: a role for ambroxol?[J]. Pulm Pharmacol Ther, 2014,28(2):98-108.
|
| [18] |
杨明杰,代敦林,余 君.大剂量氨溴索联合呼吸机对老年重症肺炎患者症状改善及炎症指标的影响[J].医药论坛杂志,2021,42(22):55-58.
|
| [13] |
Wang Y, Li X, Wang D, et al. In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant acinetobacter baumannii[J]. Lett Appl Microbiol,2020,70 (3):189-195.
|
| [19] |
冷承慧.亚胺培南西司他汀联合氨溴索治疗脓毒症的疗效及对炎症因子的影响研究[J].临床研究,2023,31(2):75-78.
|
| [14] |
李 慧,徐效峰,丘绍校.大剂量氨溴索对急性肺损伤/急性呼吸窘迫综合征疗效的系统评价[J].中国呼吸与危重监护杂志, 2012,11(5):459-464.
|
| [15] |
孔 颖.大剂量氨溴索联合左氧氟沙星治疗老年慢性阻塞性肺疾病伴重症肺炎患者的临床效果[J].医疗装备,2021,34(10):77-78.
|
| [16] |
王 芳,周秋云,鲁 涛.亚胺培南西司他丁钠或美罗培南治疗早期肺癌合并重症肺部感染[J].中国临床研究,2022,35(9):1305-1309.
|
| [17] |
李慧敏,李多磊,许晓雨,等.清开灵注射液联合亚胺培南西司他丁钠治疗老年重症肺炎的临床研究[J].现代药物与临床,2020,35(9):1777-1781.
|
| [18] |
杨明杰,代敦林,余 君.大剂量氨溴索联合呼吸机对老年重症肺炎患者症状改善及炎症指标的影响[J].医药论坛杂志,2021,42(22):55-58.
|
| [19] |
冷承慧.亚胺培南西司他汀联合氨溴索治疗脓毒症的疗效及对炎症因子的影响研究[J].临床研究,2023,31(2):75-78.
|
|
|
|
2024, Vol. 35 
